ClinicalTrials.gg
RecruitingNCT06942208FeSc2Updated Apr 17, 2026

Improving Iron Levels in Female Endurance, Intermittent, and Power/Strength Athletes Aged 16-35

An interventional study of Low-dose iron (ferrous sulfate) and Yeast-bound iron (ferrous sulfate) in Iron Deficiency, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to female participants aged 16 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by University of Calgary · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
16 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing iron in Iron Deficiencies — 5 open to participants now, 7 under way, none of them phase 3. Iron · Iron Deficiencies.

Planned enrollment
18th of 21
36 · median 111
Started
2026
with 4 others
No phase
13 of 21
3 open now
Registered
16th of 21
by date

Among the 21 studies testing iron in Iron Deficiencies, this one is the 18th largest by planned enrollment, is one of 5 that started in 2026, is one of 13 with no phase, and was the 16th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

5 of the 21 studies testing iron in Iron Deficiencies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About iron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 16 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing iron in Iron Deficiencies, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if different types and doses of oral iron supplements can improve iron levels, athletic performance, and gut health in young female athletes with low iron stores. The main questions it aims to answer are:

  • Does a low dose of yeast-bound iron improve iron status better than traditional iron supplements?
  • Do the different iron supplements cause fewer or more gastrointestinal (stomach) symptoms?
  • How do iron supplements affect exercise performance and gut bacteria?

Researchers will compare three types of iron supplements:

  • A low-dose iron supplement (40 mg)
  • A low-dose yeast-bound iron supplement (40 mg)
  • A high-dose iron supplement (150 mg)

This will help researchers find out which type of supplement is most effective and easiest on the stomach.

Participants will:

  • Take one of the three assigned iron supplements every other day for 12 weeks
  • Complete fitness tests before and after the study, including cycling and jumping tests
  • Give blood samples to measure iron levels
  • Provide stool and intestinal samples to study gut bacteria
  • Swallow a SIMBA capsule before and after the study to collect a sample from the small intestine
  • Complete regular online surveys about sleep, stress, menstrual cycles, and gut symptoms
Read the detailed description

This clinical trial is designed to evaluate and compare the effects of three oral iron supplementation strategies on iron status, gut microbiota, and athletic performance in young female athletes with suboptimal iron levels. The study compares a low-dose iron supplement, a low-dose yeast-bound iron supplement (Lalmin® Fe10), and a high-dose iron supplement. The primary goal is to identify which iron supplement improves iron status most effectively while minimizing gastrointestinal symptoms and changes to the gut microbiota.

The rationale for the study is based on the high prevalence of iron deficiency among female athletes, especially those involved in endurance and high-intensity sports. Iron plays a key role in oxygen transport, energy production, and recovery, making it essential for optimal athletic performance. However, current supplementation practices often lead to poor compliance due to side effects and low absorption rates. The yeast-bound iron product being tested is hypothesized to improve absorption and tolerability by altering the site of absorption and reducing gastrointestinal distress.

Participants will be biologically female athletes aged 16-35 with suboptimal ferritin (≤50 µg/L), who are competitively trained and meet strict health and fitness criteria. After screening, eligible participants will be randomly assigned to one of three groups and consume their assigned supplement every other day for 12 weeks. Each supplement will be encapsulated to preserve blinding and consistency.

The study involves six in-person visits:

Visit 1 Screening and Consenting:

Study investigators will reach out electronically or by phone to individuals interested in participating in the study. At this time, participants will be informed about the study and eligibility will be confirmed. Iron status will be assessed using ferritin, achieved through a forearm venipuncture. Participants with suboptimal ferritin levels (≤50 µg/L) will be asked to complete a 3-day food record over the following week on non-consecutive days. This food intake data will be used to determine energy availability to ensure participants meet the minimum requirement of >30 kcal/kg lean body mass. Those who do not meet this requirement will be excluded from further participation.

Visit 2 Baseline Testing (Week 0):

Once inclusionary criteria has been confirmed and met, participants will undergo baseline measures of iron status through a forearm blood draw, they will complete a body composition assessment to assess lean body mass, and participants will complete a cycling-based aerobic fitness test (VO2 max) to characterize their fitness level. Participants will also be sent home with a package with SIMBA capsules, fecal sample collection kit, and collection instructions.

Visit 3 Baseline Testing (Week 0):

Participants will return 48-72 hours later to complete a cycling-based anaerobic fitness test (Wingate) and a countermovement jump test to assess fitness level. After fecal sample has been retrieved and picked up by study personal, participants will begin the 12-week nutritional intervention.

Nutritional Intervention:

Participants will consume an oral iron supplement every other day for 12 weeks. Participants will take their supplement within 30 minutes of morning training. If there is no morning training, participants will be instructed to consume immediately upon waking. The total dose of elemental iron is 40mg for the low dose group, 40mg for the yeast bound iron group, and 150mg for the high dose group, contained within a gelatin capsule. The iron-complexed yeast is a pasteurized (not live) Saccharomyces cerevisiae, a common nutritional yeast. There are no limits on how much can be consumed. They will also be reminded to take with food, a few hours before or after taking other medications or natural health products and avoid coffees, teas, dairy and dairy alternatives for two hours after consumption every other day. If they miss a dose, they will be recommended to take the next dose the next day and begin dosing every other day from there. After 4 and 8 weeks of consuming the supplement, participants will return to the lab for follow-up testing, consisting of a venipuncture blood draw (visits 4 and 5) and three-day food log (visit 4 only). At these visits they will be provided with another four-week supply of capsules. Participants will then be instructed to return to the lab to retrieve another 4 weeks of capsules, 8 weeks into the intervention, before completing their 12-week post-intervention tests. The Get Active Questionnaire (GAQ) and Menstrual Disorder of Teenagers (MDOT) will be completed at baseline; the Epworth Sleepiness Scale and Menstrual Bleeding Questionnaire will be completed monthly; the Gastrointestinal Symptoms Questionnaire, Post Exercise Short Recovery Scale, and Acute Recovery and Stress Scale will be assessed weekly through Qualtrics, an online survey platform.

Visit 4 Follow-Up (Week 4):

Participants will have a blood sample drawn for assessment of iron status and be instructed to complete a 3-day food log on three-non-consecutive days over the next week.

Visit 5 Follow-Up (Week 8):

Participants will have a blood sample drawn for assessment of iron to reduce the risk of iron overload.

Visit 6 Post Intervention (Week 12):

After the 12-week intervention has concluded, participants will return to the lab to repeat the aerobic exercise test (VO2).

Visit 7 Post Intervention (Week 12):

Participants will return to the lab to repeat measures done at baseline (blood status, body composition, anaerobic fitness test (Wingate and countermovement jump test), 3-day food log, fecal sample collection kit, and SIMBA capsule). At this time, participants will return any unused capsules to be counted for assessment of compliance.

Primary outcomes include changes in markers of iron status (ferritin, hemoglobin, RBC indices). Secondary outcomes include aerobic/anaerobic performance measures, body composition (DXA), substrate metabolism, gut microbiota composition (via fecal and intestinal sampling), and self-reported gastrointestinal symptoms. Safety and tolerability will be monitored at each study visit and through participant self-report.

Data will be analyzed using both traditional statistics (e.g., ANOVA) and machine learning methods for complex 'omics' data. Results will inform better supplementation strategies for female athletes and will be shared through academic publications.

The study will contribute to a greater understanding of iron supplementation strategies that are effective, tolerable, and beneficial to performance and health.

03

Conditions studied

  • Iron Deficiency

Keywords

  • iron
  • iron deficiency
  • athletic performance
  • female athlete
  • iron supplements
  • ferritin
  • hemoglobin
  • gastrointestinal
  • microbiome
  • Exercise test
  • Yeast
  • Saccharomyces cerevisiae
  • ferrous sulphate
  • ferrous sulfate
  • Body composition
  • exercise
04

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biologically female athlete
  • Age 16-35
  • At least one year past the age of menarche
  • Complete and pass the Get Active Questionnaire (GAQ)
  • Suboptimal ferritin levels (≤50 mcg/L)
  • Provide to participate in study
  • Activity level based on Participant Classification Framework (McKay et al., 2022)

    • Tier 3: Highly Trained / National Level
    • Tier 4: Elite / International Level
  • Energy availability >30 kcal/kg LBM
  • Have access to a smartphone, tablet, or computer
  • Able to swallow a capsule sized 25mm length and 8mm width (i.e. large dose omega 3 pill)

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking
  • Anemic ( \<120g/L)
  • Regular prebiotic (fiber) or probiotic use within 4 weeks of study enrollment
  • Current laxative use
  • Are a smoker or use tobacco products
  • Consume >21 units of alcohol per week
  • Have donated blood in the previous 3 months
  • Have a \<16 but >30kg/m2
  • Are dieting for weight loss or are following a low carbohydrate diet
  • Have participated in another clinical trial within the 30 days preceding study enrollment.
  • Known allergy of to any ingredient, including non-medicinal ingredients, such as iron, yeast, cellulose, or maltodextrin
  • Are taking medications known to affect cardiovascular or metabolic responses to exercise such as beta-blockers, anti-coagulants etc. as assessed by the Principal Investigator
  • Known history of thalassemia or thalassemia trait
  • Known inherited bleeding disorder
  • Major surgery in the past 3 months
  • Chronic use of Salicylates, aspirin, , or nonsteroidal anti-inflammatory drugs
  • Have any of the following conditions: renal or gastrointestinal disorders, disease, metabolic disease, heart disease, vascular disease, rheumatoid arthritis, diabetes, poor lung function, uncontrolled blood pressure, dizziness, thyroid problems, or any other health conditions that are being treated and deemed to be able to significantly interfere with study intervention and assessment in the opinion of the Principal Investigator and Qualified Investigator
  • Have current musculoskeletal injuries that limit exercise capacity
  • Self-identifying with any kidney or gastrointestinal issues, metabolic disorders, cardiac conditions, vascular illnesses, rheumatoid arthritis, diabetes, compromised lung function, unregulated blood pressure, episodes of dizziness, thyroid complications, or any other health conditions under treatment that might potentially interfere with the study results
  • Orthopaedic issues that limit exercise ability
  • Currently/last 3 months taking prescription medications that are known to affect iron absorption (i.e. Antacids/PPIs (e.g., omeprazole), H2 Blockers (e.g., ranitidine), Tetracycline Antibiotics (e.g., doxycycline), Quinolone Antibiotics (e.g., ciprofloxacin), Cholestyramine, Colchicine, Methyldopa.)
  • Currently taking levodopa or levothyroxine
  • Currently/last 3 months taking iron containing supplements
  • Are pregnant or lactating or planning to become pregnant for the duration of the study. All participants must agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Abstinence or agrees to use contraception if planning to become sexually active
    • Hormonal contraceptives including oral contraceptives, hormone birth control patch
    • Vaginal contraceptive ring, injectable contraceptives, or hormone implant
    • Barrier methods (e.g. condoms with spermicide, diaphragms with spermicide)
    • Intrauterine devices
    • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening

Additional exclusion criteria based on use of SIMBA capsules. Following is a summary of SIMBA capsules specific exclusion criteria:

  • Currently pregnant, planning to become pregnant, or breastfeeding
  • Prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring, narrowing, or obstruction with a risk of capsule non-excretion, including, e.g. achalasia, eosinophilic esophagitis, any IBD, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.
  • History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction
  • Have any gastrointestinal inflammatory diseases, including ulcerative colitis, Crohn's disease, microscopic colitis.
  • Use of any medication in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g. opioids, prokinetics, anticholinergics, GLP-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the study visit. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.

    • Prokinetic (stimulate muscle contractions, Metoclopramide, Domperidone, Prucalopride, etc.) use. If you are not using prokinetics to treat SIBO, then you may be eligible after a 2-week washout period, and willing to not use prokinetics for the study duration.
    • Unable to stop using laxatives or prokinetic medications for 4 days before the study procedure (breath test). Laxatives can be resumed after the test is conducted.
  • Have used antibiotics (except for topical use) in the previous 12 weeks. You may be eligible to participate once a 12-week washout is completed
  • Regular use of probiotics, prebiotics, or synbiotics (including food and drinks containing added probiotics and/or probiotic yogurts with live, active cultures)
  • Have digestive problems that slow or stop food from moving properly, like a slow stomach, blocked intestines, or stiffened tissues
  • Suffer from celiac disease (treated or untreated)
  • Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome
  • History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration
  • Have had a cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable)
  • Have trouble swallowing, which could cause a risk of choking on a capsule
  • Participants scheduled for an MRI at any time during the study. You may be eligible to participate once your MRI procedure is completed.
  • Have constant constipation (IBS-C) defined as a history of less than 3 bowel movements per week
  • Any prior fecal microbiota transplantation
  • Drug use
  • Suffer from alcohol or drug abuse
  • Females of will be asked about their likelihood of being pregnant, based on factors such as recent sexual activity or use of contraception. Their self-reported confirmation of non-pregnancy will be accepted unless they express uncertainty. In cases of doubt, a urine beta-HCG pregnancy test will be required for confirmation. If you become pregnant during the course of the study, you should stop taking the supplement immediately and inform the investigators. If you are using a supplement that the investigators have deemed to not interfere with the study's intervention or assessment (e.g. vitamins, omega-3, creatine monohydrate etc.), you will be permitted to continue taking these supplements. In all cases, participants will be instructed to not change the dose of the taken supplement or introduce a new supplement unless it is medically recommended.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Low dose iron supplement

    This supplement consists of encapsulated ferrous sulphate (40 mg elemental iron).

    Dietary Supplement: Low-dose iron (ferrous sulfate)

  • Experimental
    Low dose iron supplement bound to yeast

    Low dose iron (40 mg elemental iron) in the form of yeast-bound iron, specifically Lalmin® Fe10. This supplement consists of encapsulated ferrous sulphate complexed with inactivated Saccharomyces cerevisiae (nutritional yeast).

    Dietary Supplement: Yeast-bound iron (ferrous sulfate)

  • Active comparator
    High dose iron supplement

    This supplement consists of encapsulated ferrous sulphate (150 mg elemental iron).

    Dietary Supplement: High-dose iron (ferrous sulfate)

Interventions

  • Dietary supplementIronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Encapsulated low-dose ferrous sulphate (40mg elemental iron)

  • Dietary supplementFerrous sulfateStudies of Ferrous sulfateFerrous sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Encapsulated yeast-bound low-dose ferrous sulphate (40mg elemental iron)

  • Dietary supplementIronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Encapsulated high-dose ferrous sulphate (150mg elemental iron)

06

What researchers measure

Primary outcomes

  1. Iron status blood markers

    A forearm venous blood draw

    Time frame: Baseline

  2. Iron status blood markers

    A forearm venous blood draw

    Time frame: 4 weeks

  3. Iron status blood markers

    A forearm venous blood draw

    Time frame: 8 weeks

  4. Iron status blood markers

    A forearm venous blood draw

    Time frame: 12 weeks

  5. Gut microbiota

    Effects of the various iron formulations on the gut microbiota using the SIMBA capsule and stool sample analysis. Fecal Collection: Participants will provide two stool samples to assess fecal metabolites and gut microbiota composition. Participants will be provided a stool sample collection kit that will allow them to collect the sample in the privacy of their home. The kit will contain all necessary instructions and materials required to perform the collection. Gut microbiome Assessment: Participants will ingest a SIMBA capsule pre and post intervention. The capsule captures a small fluid sample from the small intestine, which will be retrieved upon excretion to examine the gut microbiome.

    Time frame: Baseline

  6. Gut microbiota

    Effects of the various iron formulations on the gut microbiota using the SIMBA capsule and stool sample analysis. Fecal Collection: Participants will provide two stool samples to assess fecal metabolites and gut microbiota composition. Participants will be provided a stool sample collection kit that will allow them to collect the sample in the privacy of their home. The kit will contain all necessary instructions and materials required to perform the collection. Gut microbiome Assessment: Participants will ingest a SIMBA capsule pre and post intervention. The capsule captures a small fluid sample from the small intestine, which will be retrieved upon excretion to examine the gut microbiome.

    Time frame: 12 weeks

Secondary outcomes

  1. VO2 Max

    VO2 max testing on a cycling ergometer to assess peak power output, maximal oxygen consumption, and exercise thresholds. Individuals will begin with a 4-minute warm-up of low intensity, then proceed to a progressively increasing cycling challenge until they reach the point of voluntary exhaustion. Breath-by-breath measurement of gas exchange will be captured using open-circuit spirometry at rest, during exercise, and during recovery. Perceptual responses will be recorded during warm-up, every two minutes throughout exercise, and after task failure. Heart rate will be collected using a chest strap and measured throughout exercise. This method is used to evaluate the fitness levels of the participants. Metabolic cart measurements: Participants will wear a mask connected to a breath-by-breath metabolic cart to measure expired gases and minute ventilation. This equipment will continuously monitor the expired concentrations of O2 and CO2.

    Time frame: Baseline

  2. VO2 Max

    VO2 max testing on a cycling ergometer to assess peak power output, maximal oxygen consumption, and exercise thresholds. Individuals will begin with a 4-minute warm-up of low intensity, then proceed to a progressively increasing cycling challenge until they reach the point of voluntary exhaustion. Breath-by-breath measurement of gas exchange will be captured using open-circuit spirometry at rest, during exercise, and during recovery. Perceptual responses will be recorded during warm-up, every two minutes throughout exercise, and after task failure. Heart rate will be collected using a chest strap and measured throughout exercise. This method is used to evaluate the fitness levels of the participants. Metabolic cart measurements: Participants will wear a mask connected to a breath-by-breath metabolic cart to measure expired gases and minute ventilation. This equipment will continuously monitor the expired concentrations of O2 and CO2.

    Time frame: 12 weeks

  3. Wingate

    Wingate test completed on cycle ergometer to determine peak power output and fatigue index. During this test, participants will use a cycle ergometer. After a five-minute warm-up at low intensity, participants will pedal at maximum effort against a set resistance (7.5%) for 30 seconds, based on their body weight. Peak power will be assessed as well as other key performance metrics.

    Time frame: Baseline

  4. Wingate

    Wingate test completed on cycle ergometer to determine peak power output and fatigue index. During this test, participants will use a cycle ergometer. After a five-minute warm-up at low intensity, participants will pedal at maximum effort against a set resistance (7.5%) for 30 seconds, based on their body weight. Peak power will be assessed as well as other key performance metrics.

    Time frame: 12 weeks

  5. Countermovement jump test

    Researchers will use a force plate to assess low body and explosive strength. After a 10 minute warm-up where participants will perform 3 maximal CMJs, rest for two minutes, and perform a second set of 3 CMJs. Participants will complete 3-5 repetitions, with a minimum of 3, with 10-15 seconds between each jump, within a minimum of 10 seconds. Testing will occur before and after supplementation.

    Time frame: Baseline

  6. Countermovement jump test

    Researchers will use a force plate to assess low body and explosive strength. After a 10 minute warm-up where participants will perform 3 maximal CMJs, rest for two minutes, and perform a second set of 3 CMJs. Participants will complete 3-5 repetitions, with a minimum of 3, with 10-15 seconds between each jump, within a minimum of 10 seconds. Testing will occur before and after supplementation.

    Time frame: 12 weeks

  7. Body composition

    The DXA procedure uses a small amount of x-ray radiation to determine the amount of fat, bone, and muscle mass an individual has in his/her body.

    Time frame: Baseline

  8. Body composition

    The DXA procedure uses a small amount of x-ray radiation to determine the amount of fat, bone, and muscle mass an individual has in his/her body.

    Time frame: 12 weeks

  9. Gastrointestinal Health

    PROMIS and Gastrointestinal Symptom Questionnaire to assess gastrointestinal symptoms.

    Time frame: Weekly from baseline to 12 weeks

  10. Menstrual cycle

    MDOT questionnaire to assess menstrual cycle.

    Time frame: Baseline

  11. Menstrual cycle

    Menstrual Bleeding questionnaire to assess menstrual cycle.

    Time frame: baseline

  12. Menstrual cycle

    Menstrual Bleeding questionnaire to assess menstrual cycle.

    Time frame: 4 weeks

  13. Menstrual cycle

    Menstrual Bleeding questionnaire to assess menstrual cycle.

    Time frame: 8 weeks

  14. Menstrual cycle

    Menstrual Bleeding questionnaire to assess menstrual cycle.

    Time frame: 12 weeks

  15. Short Stress and Recovery Scale (SSRS)

    Short Stress and Recovery Scale (SSRS) to assess recovery and stress; higher scores under each domain indicate higher levels of stress or recovery, respectively

    Time frame: Completed weekly from baseline to 12 weeks

  16. Activity Readiness

    Get Active Questionnaire to assess readiness for exercise.

    Time frame: Baseline

  17. Sleep

    Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness

    Time frame: Baseline

  18. Sleep

    Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness

    Time frame: 4 weeks

  19. Sleep

    Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness

    Time frame: 8 weeks

  20. Sleep

    Epworth Sleepiness Scale (ES) to assess sleep; possible range 0-24; higher scores indicate higher levels of sleepiness

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pantopoulos K. Oral iron supplementation: new formulations, old questions. Haematologica. 2024 Sep 1;109(9):2790-2801. doi: 10.3324/haematol.2024.284967. PubMed 38618666 ↗
  • McKay AKA, Stellingwerff T, Smith ES, Martin DT, Mujika I, Goosey-Tolfrey VL, Sheppard J, Burke LM. Defining Training and Performance Caliber: A Participant Classification Framework. Int J Sports Physiol Perform. 2022 Feb 1;17(2):317-331. doi: 10.1123/ijspp.2021-0451. Epub 2022 Dec 29. PubMed 34965513 ↗
  • McKay AKA, Sim M, Moretti D, Hall R, Stellingwerff T, Burden RJ, Peeling P. Methodological Considerations for Investigating Iron Status and Regulation in Exercise and Sport Science Studies. Int J Sport Nutr Exerc Metab. 2022 Apr 1;32(5):359-370. doi: 10.1123/ijsnem.2021-0343. Print 2022 Sep 1. PubMed 35365588 ↗
  • McCormick R, Moretti D, McKay AKA, Laarakkers CM, Vanswelm R, Trinder D, Cox GR, Zimmerman MB, Sim M, Goodman C, Dawson B, Peeling P. The Impact of Morning versus Afternoon Exercise on Iron Absorption in Athletes. Med Sci Sports Exerc. 2019 Oct;51(10):2147-2155. doi: 10.1249/MSS.0000000000002026. PubMed 31058762 ↗
  • Low MS, Speedy J, Styles CE, De-Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev. 2016 Apr 18;4(4):CD009747. doi: 10.1002/14651858.CD009747.pub2. PubMed 27087396 ↗
  • Erdman KA, Fung TS, Doyle-Baker PK, Verhoef MJ, Reimer RA. Dietary supplementation of high-performance Canadian athletes by age and gender. Clin J Sport Med. 2007 Nov;17(6):458-64. doi: 10.1097/JSM.0b013e31815aed33. PubMed 17993788 ↗
  • Cordova A, Mielgo-Ayuso J, Fernandez-Lazaro CI, Caballero-Garcia A, Roche E, Fernandez-Lazaro D. Effect of Iron Supplementation on the Modulation of Iron Metabolism, Muscle Damage Biomarkers and Cortisol in Professional Cyclists. Nutrients. 2019 Feb 27;11(3):500. doi: 10.3390/nu11030500. PubMed 30818782 ↗
  • Attwell C, McKay A, Sim M, Dugan C, Nicholas J, Hopper L, Peeling P. Timing is everything, but does it really matter? Impact of 8-weeks morning versus evening iron supplementation in ballet and contemporary dancers. Eur J Sport Sci. 2023 Dec;23(12):2275-2282. doi: 10.1080/17461391.2023.2224285. Epub 2023 Jul 10. PubMed 37291690 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 6 months is below that.

Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 24, 2025
StartActual
Mar 26, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942208
Collaborators
Mitacs, Natural Sciences and Engineering Research Council, Canada
Responsible party
Jane Shearer (Professor, University of Calgary) — Principal investigator
First posted
Apr 24, 2025
Start date
Mar 26, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

Lauren Hundseth
Contact
lauren.hundseth@ucalgary.ca
(306) 380-5898
Jane Shearer
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iron · Ferrous sulfate

Start the discussion